by Kinnate Biopharma | Sep 12, 2020
Our FGFR program, KIN-3248 is a small-molecule kinase inhibitor that target cancer-associated alterations in FGFR2 and FGFR3 genes, which are among the most commonly identified oncogenic drivers detected in solid tumor cancers. KIN-3248 aims to address the primary...
by Kinnate | Sep 12, 2020
by Kinnate Biopharma | Sep 12, 2020
Recent Comments